Diabetes drug shows promise in fighting advanced prostate cancer
NCT ID NCT07310433
Summary
This study is testing if adding a common diabetes drug, dapagliflozin, to standard hormone therapy helps control advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It will involve 60 men whose cancer has spread and who are starting a specific type of hormone therapy. The main goal is to see if the combination delays cancer growth longer than the standard treatment alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huashan Hospital
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ruijin Hospital
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.